ReproCell Stock

ReproCell Net Debt / EBITDA

The Net Debt to EBITDA of ReproCell (4978.T) as of Sep 4, 2026 is 35.21. In the previous year, Net Debt to EBITDA was 16.71 — a change of 110.72% (higher).

Net Debt / EBITDA

35.21

YoY

110.72%

Last updated:

Net Debt to EBITDA of ReproCell is 2026 35.21 . Net Debt to EBITDA of ReproCell was 2025 16.71 . It decreases by 110.72% higher compared to the previous year.

The ReproCell Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
6.94 JPY
Jan 1, 2019
7.55 JPY
Jan 1, 2020
5.89 JPY
Jan 1, 2021
4.43 JPY
Jan 1, 2022
7.25 JPY
Jan 1, 2023
18.62 JPY
Jan 1, 2024
16.71 JPY
Jan 1, 2025
35.21 JPY
The ReproCell Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
35.21+110.72%
16.71-10.25%
18.62+156.73%
7.25+63.82%
4.43-24.79%
5.89-22.00%
7.55+8.73%
6.94-7.42%
7.50+3.50%
7.24+10.87%
6.53-88.03%
54.56+1,376.20%
3.70+102.05%
1.83-23.95%
2.41-27.14%
3.30-2.74%
3.39+930.43%
0.33
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Net Debt to EBITDA of ReproCell is 35.21 in 2026.

Net Debt to EBITDA of ReproCell changed from 16.71 to 35.21, representing a 110.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA ReproCell since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's ReproCell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — ReproCell

All Key Metrics — ReproCell